A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus

• Status: Withdrawn
• Trial end date: 2017-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective, open-label, within-subject, multi-center pilot study of Lymphoseek in the detection of lymph nodes in subjects with known squamous cell carcinoma of the anus.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cardinal Health 414, LLC; Navidea Biopharmaceuticals
• Treatments: Dextrans; Technetium Tc 99m Pentetate

Criteria

Inclusion Criteria:

• Subject has provided written informed consent with Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization

• Has histologically confirmed squamous cell carcinoma of the anus (anal canal or perianus)

• Has a documented clinical stage using the tumor, lymph node, metastasis staging (TNM) classification system that was established by at least physical exam with manual palpation, digital anorectal examination, high-resolution anoscopy and PET/CT imaging evaluation of the bilateral inguinal area

• Is at least 18 years of age at the time of consent

• Has an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 to 3

• If of childbearing potential, the subject has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year

Exclusion Criteria:

• The subject has had radiation therapy, chemotherapy or immunotherapy within the 30 days prior to Lymphoseek administration

• Has had previous surgery or node dissection (exclusive of fine needle aspiration) or radiation to node basins that would be involved in the intraoperative lymphatic mapping procedure

• Has a known allergy to dextran

• Is breast-feeding or pregnant

• Before the administration of Lymphoseek, has received any radiopharmaceutical within 7 radioactive half-lives of that radiopharmaceutical

• Has received an investigational product within the 30 days prior to Lymphoseek administration